brand name drugs

Is there a simple fix for the Part D discount program?A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.
Expedited FDA approval plays dominant role in drug approvalsLast year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017.
Brand-name patent losses raise pharma cost concernsA number of traditional brand-name pharmaceuticals have lost, or will lose, patent protection this year. What does this mean over the longer-term for controlling costs?
Brand Rx drug spending rises; overall spending growth steadyA new report looks specifically at spending on healthcare for the privately insured in the U.S in 2014. Here are the findings.
Senators target pay-for-delay pharma dealsU.S. Senators Amy Klobuchar (D-Minn.) and Chuck Grassley (R-Iowa) recently reintroduced legislation that would make it illegal for brand-name drug manufacturers to pay-off other drug manufacturers to keep generic versions of brand-name drugs off the market.
2014 drug costs soar, no end in sightWhile hepatitis C drugs Solvani, Harvoni, and Viekira Pak have been in the news recently because of their high price tag, and Express Scripts’ and CVS Health’s exclusive agreements with the drugmakers, they are not the only culprits in soaring drug costs.
[BLOG]: Hepatitis C market competition arrives for 2015There is plenty of activity already in the hepatitis C market as competition has arrived for 2015, including CVS Health versus Express Scripts and Gilead Sciences versus AbbVie, over FDA-approved hepatitis C treatments. This will have implications for retail prescriptions as well as continuity-of-care programs within non-Medicare accountable care organizations (ACOs) and health systems.
[BLOG]: Cost containment through the use of generic medicationsThere’s no hiding that hospital pharmacies have long been considered cost centers for healthcare systems. That positioning has been accentuated over the past 5 years, as the healthcare industry has seen a steady increase in high-cost, brand-name specialty medications that range from hundreds to thousands, sometimes tens of thousands, of dollars per dose. Nearly every hospital, however, has untapped opportunities to substantially improve efficiencies and improve costs. One important factor is improving how these hospitals use generic medications.
FDA concerned about generic ADHD drugsFDA has warned about 2 approved generic versions of Concerta tablets to treat attention-deficit hyperactivity disorder (ADHD).
Generics vs. brand-name drugs—different but still safeDespite some perceptions, generic pharmaceutical drugs are not necessarily less effective than their branded counterparts. But their true claim to fame is in cheaper pricing, undercutting the brand-name alternatives sometimes by orders of magnitude. But according to Dr. Milton Hom, OD, FAAO, price shouldn't take on the main consideration.